StreetAlpha.app
Home › Stocks › RNAC

Cartesian Therapeutics, Inc. (RNAC)

$6.14
▲ +4.24%
LAST CLOSE · NOV 20

Cartesian Therapeutics develops mRNA-based cell therapies for autoimmune diseases, starting with its lead candidate for myasthenia gravis. It last closed at $6.14 on Nov 20, up 4.24% on the day. The next earnings report for RNAC is expected around Mon, Mar 8, 2027. For the quarter ended Sep 2026, RNAC reported EPS of -$0.38 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 7.1% the session after earnings. Over the last 12 months RNAC insiders bought $206K of stock on the open market and sold $259K, according to SEC Form 4 filings.

AI Auto Pilots
Is RNAC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RNAC.

Key Stats

Last 12 months
Results
Revenue
$1.0M
−6.0% vs a year ago
Net income
−$127.5M
−12435.2% margin
EPS (diluted)
−$4.78
Free cash flow
−$89.9M
−8770.0% margin
Valuation
Market cap
$187.3M
30.5M shares
P/E
–
No P/E while losing money
Price to sales
182.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$123.0M
At Sep 30
Debt
$50.2M
At Sep 30
Shareholder equity
−$130.5M
Shares outstanding
30.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $85.1M$85.1MFY2021FY2022: $110.8M$110.8MFY2022FY2023: $26.0M$26.0MFY2023FY2024: $38.9M$38.9MFY2024FY2025: $2.8M$2.8MFY2025

From RNAC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · Time not announced
Reported EPS
-$0.38
Quarter ended Sep 2026
Year ago EPS
-$1.38
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.12Dec '24Mar 2025: -$0.68Mar '25Jun 2025: $0.50Jun '25Sep 2025: -$1.38Sep '25Dec 2025: -$3.57Dec '25Mar 2026: -$1.46Mar '26Jun 2026: $0.46Jun '26Sep 2026: -$0.38Sep '26Latest -$0.38
Revenue by quarter
Mar 2025: $1.1MMar '25Jun 2025: $298,000Jun '25Sep 2025: $452,000Sep '25Dec 2025: $947,000Dec '25Mar 2026: $78,000Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How RNAC moved after its last 8 reports
Average move the session after a report ±7.1%
Nov 5, 2026Time not announced−0.6%
Aug 6, 2026Time not announced+4.9%
Apr 30, 2026Time not announced−3.9%
Mar 9, 2026Time not announced+31.7%
Nov 6, 2025Time not announced−1.6%
Aug 7, 2025Time not announced−6.6%
May 8, 2025Time not announced+2.7%
Mar 13, 2025Time not announced−5.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RNACStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on RNAC: 0 upgrades, 0 downgrades, 0 initiations
HC WainwrightReiterated
Nov 21  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on RNAC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RNAC

Technical Analysis

RNAC · as of the Nov 20 close · updated each morning
Downtrend

The stock is 6% below its 20 day and 12% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the Pivot at $6.12, and the nearest resistance the Pivot R1 at $6.34.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 7.7%/day
Key levels
$11.0052 week high+79.2%
$7.91100 day average+28.8%
$7.60200 day average+23.8%
$6.8850 day average+12.1%
$6.71Swing high (Oct 21)+9.3%
$6.5320 day average+6.4%
$6.34Pivot R1+3.3%
$6.14Last close
$6.12Pivot−0.3%
$6.07Swing low (Oct 26)−1.1%
$5.91Pivot S1−3.7%
$5.6052 week low−8.8%
Indicators
RSI (14)42.44Middle of its rangeNeutral
MACD-0.22Below its signal lineBearish
Stochastic13.6Near the bottom of its rangeOversold
ADX (14)13.0No clear trend
Williams %R-83.8Oversold below −80, overbought above −20Oversold
CCI (20)-91.8Oversold below −100, overbought above 100Neutral
Rate of change−18.5%Change over 10 sessionsBearish
ATR (14)$0.47Typical daily range, 7.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNAC

What happened before

See how RNAC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RNAC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RNAC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RNACHow many large options trades hit RNAC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RNAC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●44 buying vs 42 selling
  • ●Held by funds +0.2 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10095+5.3%
In funds' top 1000–
Held by funds28.7%28.5%+0.2 pts
New / increased11 / 3324 / 44−35.3%
Reduced / sold out35 / 712 / 12+75.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RNAC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RNAC Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$206K1 buy · 1 insider
Sold$259K3 sales · 3 insiders
2025-12 bought $206K2026-01 sold $259KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jan 6Blaine DavisCFOSale10,591$6.82$72K
Jan 6Milos MiljkovicChief Medical OfficerSale3,573$6.82$24K
Jan 6Carsten BrunnPresident and CEOSale23,766$6.82$162K
Dec 4, 2025Timothy C BarabeDirectorBuy30,000$6.86$206K
Apr 11, 2025Timothy A SpringerDirectorBuy149,075$10.21$1.5M
Mar 20, 2025Timothy A SpringerDirectorBuy89,863$15.26$1.4M
Every insider buy and sale for RNAC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RNAC insider trades →

From SEC Form 4 filings by RNAC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNAC is in one of them and how their past RNAC trades turned out.

RNAC in the AI portfolios
Loading…

RNAC News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RNAC in an article yet. Here's the latest on the wider market.

RNAC in the news

About Cartesian Therapeutics

Cartesian Therapeutics is a biotechnology company based in Frederick, Maryland, that is developing cell therapies for autoimmune diseases. Its approach uses mRNA to deliver a chimeric antigen receptor into a patient's own immune cells, which are then returned to the patient for outpatient treatment. Its lead product candidate, Descartes-08, is in clinical development for myasthenia gravis and certain myositis conditions. The company's target customers are patients with these conditions, and its products are not yet approved for sale.

Headquarters
Frederick, MD
Founded
2008